Online inquiry

IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ70MR)

This product GTTS-WQ70MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets H1-0 gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_005318.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ70MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11040MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ3137MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ3680MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ10979MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ949MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10893MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ3972MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ3638MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW